Immunotherapy for Alzheimer's disease
Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.
| Errataetall: |
CommentIn: Ugeskr Laeger. 2016 Jun 13;178(24):. - PMID 27292830 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:178 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 178(2016), 3 vom: 18. Jan., Seite V07150588 |
| Sprache: |
Dänisch |
|---|
| Weiterer Titel: |
Immunterapi mod Alzheimers sygdom |
|---|
| Beteiligte Personen: |
Falkentoft, Alexander Christian [VerfasserIn] |
|---|
| Themen: |
5D6PWO0333 |
|---|
| Anmerkungen: |
Date Completed 06.11.2018 Date Revised 06.11.2018 published: Print CommentIn: Ugeskr Laeger. 2016 Jun 13;178(24):. - PMID 27292830 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM256883173 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM256883173 | ||
| 003 | DE-627 | ||
| 005 | 20231224181624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||dan c | ||
| 028 | 5 | 2 | |a pubmed24n0856.xml |
| 035 | |a (DE-627)NLM256883173 | ||
| 035 | |a (NLM)26815584 | ||
| 035 | |a (PII)V07150588 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Falkentoft, Alexander Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy for Alzheimer's disease |
| 246 | 3 | 3 | |a Immunterapi mod Alzheimers sygdom |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2018 | ||
| 500 | |a Date Revised 06.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Ugeskr Laeger. 2016 Jun 13;178(24):. - PMID 27292830 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a solanezumab |2 NLM | |
| 650 | 7 | |a 5D6PWO0333 |2 NLM | |
| 650 | 7 | |a bapineuzumab |2 NLM | |
| 650 | 7 | |a NC11WKO35D |2 NLM | |
| 700 | 1 | |a Hasselbalch, Steen Gregers |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 178(2016), 3 vom: 18. Jan., Seite V07150588 |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:178 |g year:2016 |g number:3 |g day:18 |g month:01 |g pages:V07150588 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 178 |j 2016 |e 3 |b 18 |c 01 |h V07150588 | ||